Boston-based biotech company Solu Therapeutics raised USD 31 million in a seed financing round co-led by Longwood Fund and Santé Ventures, with participation from DCVC Bio, Astellas Venture Management, and Alexandria Venture Investments.

The funds will be utilized to leverage and develop Solu Therapeutics' proprietary CyTaC platform and advance its lead oncology program into clinical trials within two years, alongside other product candidates through pre-clinical development.

Solu Therapeutics focuses on eliminating disease-driving cells in cancer, immunology, and autoimmunity. Its CyTaC platform and drug candidates, in-licensed from GSK, enable the development of next-generation medicines that combine the efficacy of antibodies with the binding capacity of small molecules. The platform has the potential to target new tumor-associated antigens, deplete pathogenic immune cells, and extend the half-life of small molecule antagonists and agonists.